Core Viewpoint - The stock of Haishike experienced a decline of 2.02% on September 16, with a trading price of 55.31 yuan per share and a total market capitalization of 61.943 billion yuan. The company has seen a year-to-date stock price increase of 67.71% but has faced recent declines over the past five and twenty trading days [1]. Financial Performance - As of June 30, Haishike reported a revenue of 2.001 billion yuan for the first half of 2025, reflecting a year-on-year growth of 18.63%. However, the net profit attributable to shareholders decreased by 21.79% to 129 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Structure - The number of shareholders for Haishike increased by 25.93% to 11,400 as of June 30, with an average of 42,147 circulating shares per shareholder, a decrease of 28.64% [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A, which increased its holdings by 5.3574 million shares, and Industrial Bank's Frontier Medical Stock A, which increased its holdings by 5.4 million shares [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局下发的1类创新药安 瑞克芬注射液（商品名称：思舒静?，研发代号：HSK21542）《药品注册证书》，现将相关情况公告如 下： 一、药品及申请基本信息 药品名称：安瑞克芬注射液 受理号：CXHS2400097 证书编号：2025S02878 批准文号：国药准字H20250014 注册分类：化学药品1类 剂 型：注射剂 规 格：1ml∶0.1mg 适 应 症：本品用于维持性血液透析的慢性肾脏疾病相关中重度瘙痒成人患者。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准增加适应症，新增适应症为"治疗成人维持性血液透析患者的慢性肾脏疾病相关的中度至重度瘙 痒"，发给药品注册证书。 二、研发项目简介 HSK21542是我司自主研发的高选择性外周kappa 阿片受体（κ Opioid Receptor，KOR）激动剂。临床研 究结果表明，HSK21542注 ...

本次权益变动后，申萍与其一致行动人王俊民合计持有公司股份由4.49亿股减少至4.48亿股，合计持股 比例由40.11%减少至40.00%，变动后比例触及1%及5%的整数倍。《每日经济新闻》记者注意到，今年 8月，海思科股价刚创历史新高。 9月14日下午，海思科（002653.SZ，股价56.45元，市值632.19亿元）公告称，近日，公司收到控股股东 王俊民之一致行动人申萍《关于减持公司股份的告知函》，获悉申萍于2025年9月1日至2025年9月12日 期间以集中竞价方式减持公司股份125万股，占公司总股本的0.11%。据了解，申萍与王俊民为夫妻关 系。 另一边，海思科持续推进定增事项。今年7月，海思科公告称，深交所已受理其向特定对象发行股票的 申请，公司拟发行不超过7000万股，募集资金总额不超过13.65亿元。控股股东之一致行动人申萍此前 已减持超600万股 每经记者｜陈星 每经编辑｜董兴生 在此之前，海思科在2023年还完成了一次8亿元的融资。 今年上半年，海思科实现营业收入20.0亿元，同比上升18.63%；归母净利润为1.29亿元，同比下降 21.79%；扣非归母净利润为1.45亿元，同比上升90. ...

格隆汇9月15日丨海思科(002653.SZ)公布，近日收到国家药品监督管理局下发的1类创新药安瑞克芬注 射液（商品名称：思舒静，研发代号：HSK21542）《药品注册证书》，HSK21542是我司自主研发的高 选择性外周kappa阿片受体（κOpioidReceptor，KOR）激动剂。临床研究结果表明，HSK21542注射液能 显著缓解瘙痒，主要疗效指标和次要疗效指标均显著优于安慰剂组，且HSK21542注射液安全性良好可 控。该新获批适应症于2024年7月被纳入优先审评审批程序，现获批上市，有望为患者提供更好的止痒 选择。 ...

人民财讯9月15日电，海思科（002653）9月15日晚间公告，公司于近日收到国家药品监督管理局下发的 1类创新药安瑞克芬注射液(商品名称：思舒静，研发代号：HSK21542)《药品注册证书》。新增适应症 为"治疗成人维持性血液透析患者的慢性肾脏疾病相关的中度至重度瘙痒"。 ...

海思科（002653）(002653.SZ)公告，公司近日收到国家药品监督管理局下发的1类创新药安瑞克芬注射 液(商品名称：思舒静，研发代号：HSK21542)《药品注册证书》，本次新增适应症为"治疗成人维持性 血液透析患者的慢性肾脏疾病相关的中度至重度瘙痒"。 ...

证券代码：002653 证券简称：海思科 公告编号：2025-102 海思科医药集团股份有限公司 关于 1 类创新药安瑞克芬注射液 新适应症获批的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 海思科医药集团股份有限公司（以下简称"公司"）于近日收到 国家药品监督管理局下发的 1 类创新药安瑞克芬注射液（商品名称： 思舒静®，研发代号：HSK21542）《药品注册证书》，现将相关情况 公告如下： 一、 药品及申请基本信息 药品名称：安瑞克芬注射液 适 应 症：本品用于维持性血液透析的慢性肾脏疾病相关中重度 瘙痒成人患者。 特此公告。 2 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准增加适应症，新增适应症 为"治疗成人维持性血液透析患者的慢性肾脏疾病相关的中度至重 度瘙痒"，发给药品注册证书。 二、 研发项目简介 HSK21542 是我司自主研发的高选择性外周 kappa 阿片受体（κ Opioid Receptor，KOR）激动剂。临床研究结果表明，HSK21542 注 射液能显著缓解瘙痒，主要疗效指标 ...

格隆汇9月15日｜海思科(002653.SZ)公告称，公司收到国家药品监督管理局下发的1类创新药安瑞克芬 注射液《药品注册证书》，批准增加适应症为"治疗成人维持性血液透析患者的慢性肾脏疾病相关的中 度至重度瘙痒"。该新获批适应症于2024年7月被纳入优先审评审批程序，现获批上市。此外，安瑞克芬 注射液已于2025年5月首次获批"用于治疗腹部手术后的轻、中度疼痛"适应症，且用于骨科手术术后镇 痛适应症的Ⅲ期临床研究正在顺利进行中。 ...

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]

Core Viewpoint - The stock of Haishike experienced a decline of 2.03% on September 15, 2023, with a current price of 56.90 CNY per share and a total market capitalization of 63.723 billion CNY, despite a year-to-date increase of 72.53% [1] Financial Performance - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - Cumulative cash dividends since the A-share listing amount to 3.673 billion CNY, with 687 million CNY distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.93% to 11,400, with an average of 42,147 circulating shares per shareholder, down by 28.64% [2] - The top ten circulating shareholders include several funds, with notable increases in holdings by China Europe Medical Health Mixed A and Industrial Bank Frontier Medical Stock A [3]